Chiesi Farmaceutici S.p.a.
Clinical trials sponsored by Chiesi Farmaceutici S.p.a., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Heartburn pill may alter Body's processing of new drug Results expected Dec 2026 (estimated)
- New nasal spray drug enters first human safety tests Results expected Feb 2027 (estimated)
- Eco-Friendly asthma inhaler put to the test Results expected Jun 2027 (estimated)
-
New COPD inhaler Add-On studied, but trial halted early
Disease control Stopped earlyThis study tested two doses of an inhaled drug called CHF6001 (Tanimilast) added to standard triple therapy in people with severe COPD and chronic bronchitis. The goal was to see if it could reduce the number of moderate or severe flare-ups over a year. The trial was terminated e…
Phase 3 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New inhaler aims to tame uncontrolled asthma Flare-Ups
Disease control Stopped earlyThis study tested an experimental inhaler (CHF6001) added to standard asthma medicines in 517 adults with uncontrolled asthma. The goal was to see if it could reduce severe asthma attacks over one year. The trial was stopped early, and results are not yet available.
Phase 2 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
COPD drug trial halted: new Add-On therapy falls short
Disease control Stopped earlyThis study tested an inhaled drug called CHF6001 (Tanimilast) in people with COPD and chronic bronchitis who were already on triple therapy. The goal was to see if adding this drug could reduce flare-ups. The trial was stopped early and involved about 4,700 participants.
Phase 3 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC